Press Release: Efficacy of Osimertinib (AZD9291) against EGFRvIII-positive Glioblastoma Presented at Society for Neuro-Oncology 2017 Annual Meeting

Dr. Madan Kwatra, Director of the Glioblastoma Drug Discovery Group at Duke, gave an oral presentation at the 2017 annual meeting for the Society of Neuro-Oncology (SNO) held in San Francisco from November 16 to 19. The presentation was entitled: A Precision Medicine Approach to Target EGFRvIII in GBM: Osimertinib (AZD9291) Inhibits the Growth of EGFRvIII-Positive Glioblastoma Stem Cells and Increases Survival of Mice Bearing Intracranial EGFRvIII-Positive GBM. Collaborators included: Cory Nanni, Callie Roberts, Shawn Kwatra, Mark R Gilbert, Glenn J Lesser.

Read more: https://academic.oup.com/neuro-oncology/article-abstract/19/suppl_6/vi82/4591000?redirectedFrom=fulltext